CSAClinical-Stage Asset Intelligence
Catalyst calendar Get the data
EN
Home / Merck & CO INC. (MRK) / zilovertamab vedotin
Forward catalyst · MRK

zilovertamab vedotin

Sponsor Merck & CO INC. · listed as MRK

READOUT Phase 2/3 Confidence: medium Source: clinicaltrials

zilovertamab vedotin is a clinical-stage drug asset sponsored by Merck & CO INC., listed as MRK. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Sep 24, 2027 (day precision, medium confidence), tied to trial NCT05139017. The asset is in Phase 2/3 and currently recruiting, studied in DLBCL. It appears across 2 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT
Expected date2027-09-24
As disclosedSep 24, 2027
Date precisionday
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT05139017
PhasePHASE2;PHASE3
StatusRECRUITING
Lead sponsorMerck Sharp & Dohme LLC
Listed asMRK
Condition(s)DLBCL; Diffuse Large B-Cell Lymphoma
!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,221 forward catalysts, 955 of them linked to 124 listed sponsors.

Get the full dataset — $499 →   More MRK catalysts

Related catalysts and sponsor